3 results
Primary Objective• To assess the effect of ALX148 + pembrolizumab + 5FU + platinum on 12-month overall survival (OS) rate and objective response rate (ORR)in patients with metastatic or unresectable, recurrent HNSCC who have not yet been treated…
There is need for evidence-based and reproducible data comparing the safety, longevity and patient satisfaction propensity of the various HA soft tissue filler products. In a survey among 67 Dutch cosmetic physicians in 2014, the Dutch National…
We will assess the safety of adalimumab-800CW through the evaluation of both vital signs after tracer administration and possible (severe) adverse events (SAE/AE*s). Importantly, we will determine the feasibility of molecular fluorescence imaging…